Anbio Biotechnology (NNNN) Other Non-Current Assets (2023 - 2024)
Anbio Biotechnology's quarterly Other Non-Current Assets came in at $387440.0 in Q4 2024, up 804.49% year-on-year from $42835.0 in Q1 2024, and up 804.49% quarter-over-quarter from $42835.0 in Q4 2023.
Anbio Biotechnology has reported Other Non-Current Assets for 2 years, with the latest figure at $387440.0 in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Assets rose 804.49% year-over-year to $387440.0; the trailing twelve-month figure through Dec 2024 stood at $387440.0 (up 804.49% YoY), and the FY2024 full-year result was $387440.0, up 804.49% from the prior year.
- Other Non-Current Assets for Q4 2024 stood at $387440.0, up from $42835.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $387440.0 in Q4 2024, with the low at $42835.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 156.17 Bn | 151.78 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.51 Bn | 40.49 Bn | 2.15 Bn | 2.43 Bn |
| 3 | Resmed | 30.43 Bn | 28.77 Bn | 890.98 Mn | 210.73 Mn |
| 4 | West Pharmaceutical Services | 22.78 Bn | 22.26 Bn | 296.40 Mn | 81.30 Mn |
| 5 | Solventum | 13.39 Bn | 13.39 Bn | 1.10 Bn | 848.00 Mn |
| 6 | Cooper Companies | 12.33 Bn | 12.20 Bn | 695.20 Mn | 688.40 Mn |
| 7 | Align Technology | 11.65 Bn | 10.59 Bn | 736.59 Mn | 39.83 Mn |
| 8 | Baxter International | 9.81 Bn | 7.77 Bn | 891.00 Mn | 692.00 Mn |
| 9 | Aptargroup | 7.39 Bn | 7.19 Bn | 351.91 Mn | 159.52 Mn |
| 10 | Anbio Biotechnology | 1.32 Bn | 1.31 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 387,440.00 |
| Dec 31, 2023 | 42,835.00 |